AstraZeneca and Incyte to study cancer drugs together

LONDON Wed May 14, 2014 2:18am EDT

LONDON May 14 (Reuters) - AstraZeneca has signed a clinical study collaboration with U.S. biotech company Incyte , highlighting its desire to push ahead with drug development despite an unwanted $106 billion bid approach from Pfizer.

The agreement will test a combination of two different drugs designed to boost the immune system to help it fight tumours - AstraZeneca's MEDI4736 and Incyte's INCB24360 - in a Phase I/II clinical study, the British firm said on Wednesday.

(Reporting by Ben Hirschler; editing by Jason Neely)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.